Panelists discuss how the primary unmet needs include better treatments for seronegative and ocular-only patients, achieving minimal symptom expression in more than the current 45% to 50% of patients, and developing therapeutic biomarkers to guide personalized treatment selection.
The pediatrician in chief at Johns Hopkins Children’s Center outlined the logistical, ethical, and regulatory hurdles of conducting pediatric MS trials, emphasizing the need for faster, more inclusive study designs to bring emerging therapies to clinic. [WATCH TIME: 5 minutes]
At CNS 2025, the child neurologist at Rady Children's Hospital-San Diego talked about the expanding role of genetics for diagnosis and treatment in pediatric neurology. [WATCH TIME: 5 minutes]
The professor of neurology at Barts and London School of Medicine and Dentistry discussed data from the phase 3b ORATORIO-HAND trial, which tested ocrelizumab’s effect in patients with more advanced primary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
Experts discuss extended interval dosing (EID) of anti-CD20 therapies in multiple sclerosis (MS) as a promising strategy to maintain disease control while potentially reducing immunosuppression-related risks, highlighting early positive clinical experiences and the importance of careful patient selection and ongoing monitoring.
Experts discuss the rationale and patient-specific considerations for de-escalating therapy in multiple sclerosis (MS), particularly for those on anti-CD20 treatments, emphasizing the balance between maintaining disease stability and minimizing long-term risks such as infections and treatment burden through tailored adjustments based on clinical, radiological, and individual factors.
The pediatrician in chief at Johns Hopkins Children’s Center provided clinical insights on new findings demonstrating ocrelizumab’s potential in treating pediatric multiple sclerosis. [WATCH TIME: 4 minutes]
The pediatrician-in-chief at Johns Hopkins Children’s Center shared her reaction to receiving this year’s Bernard Sachs Award in recognition of her contributions to child neurology. [WATCH TIME: 5 minutes]
In this final segment, Perry reflects on how zorevunersen represents a shift toward disease-modifying therapies in epilepsy and what this means for the future of genetic epilepsies. [WATCH TIME: 2 minutes]
Neurology News Network. for the week ending October 11, 2025. [WATCH TIME: 4 minutes]
In this fourth segment, Scott Perry, MD, outlines the design of the registrational EMPEROR trial and what it aims to confirm about zorevunersen’s long-term safety and clinical benefit. [WATCH TIME: 2 minutes]
At CNS 2025, the executive director at the Child Neurology Foundation presented on the importance of collaboration among clinicians and advocacy groups to connect families with care support services. [WATCH TIME: 4 minutes]
In this segment, epileptologist Scott Perry, MD, discusses zorevunersen’s effects on Vineland-3 scores and why improvements in communication, cognition, and adaptive behavior matter in Dravet syndrome. [WATCH TIME: 3 minutes]
Joseph Vithayathil, MD, discusses being awarded the Elterman Research Grant at the 2025 CNS Annual Meeting in Charlotte, North Carolina.
Panelists discuss how different FcRn inhibitors vary in administration routes, dosing schedules, and adverse event profiles, with efgartigimod offering cyclical therapy while nipocalimab provides maintenance dosing. Patients may respond differently to various agents, requiring individualized treatment approaches.
Panelists discuss how FcRn inhibitors work by blocking antibody recycling pathways while complement inhibitors prevent membrane attack complex formation at the neuromuscular junction, with both classes showing transformative efficacy but requiring careful patient selection and safety monitoring.
The associate professor and clinician-scientist at the University of Toronto spoke to the current understanding of protein waste clearance in neurodegeneration. [WATCH TIME: 4 minutes]
Epileptologist Scott Perry, MD, reviews findings from the early-phase Monarch and Admiral trials, highlighting zorevunersen’s dose-response profile, seizure reduction, and safety outcomes. [WATCH TIME: 3 minutes]
In this kick-off segment, epilepsy expert Scott Perry, MD, explains how zorevunersen uses antisense oligonucleotide technology to correct SCN1A gene expression and address the underlying cause of Dravet syndrome.
Experts discuss long-term management strategies for stable multiple sclerosis, including continuing current therapy, careful treatment discontinuation, de-escalation, and switching therapies, all tailored to individual patient needs to balance disease control with minimizing risks and treatment burden.
Experts discuss the infection risks associated with long-term anti-CD20 therapies in multiple sclerosis, emphasizing the need for careful monitoring, patient-specific risk assessment, and tailored de-escalation strategies to balance effective disease control with minimizing treatment-related adverse effects.
The chief of the Movement Disorders Division at Yale School of Medicine discusses the nuance around patient choice in Huntington disease testing and providing treatment regardless of confirmation. [WATCH TIME: 3 minutes]
The chief medical officer of Gain Therapeutics discusses the challenges that are unaddressed with currently available treatments for Parkinson, and how investigational treatments like GT-02287 might address those needs. [WATCH TIME: 3 minutes]
The neurologist at University of British Columbia discussed how breakdowns in brain organization and compensatory mechanisms may influence progression in Parkinson disease. [WATCH TIME: 5 minutes]
The chief medical officer of Gain Therapeutics discusses GT-02287, a promising treatment for Parkinson that has shown strong safety and tolerability in an ongoing phase 1 trial. [WATCH TIME: 3 minutes]
In this final episode, Riley Bove, MD, considers the next phase of MS research, emphasizing the need for innovative trial designs to address sequencing, discontinuation, and subgroup-specific treatment strategies.
In this clip, a multiple sclerosis expert reflects on how ofatumumab’s role has expanded since FDA approval in 2020, from first-line use to special populations, and what this means for daily practice.
Neurology News Network. for the week ending October 4, 2025. [WATCH TIME: 4 minutes]
Riley Bove, MD, an associate professor of neurology at UCSF, breaks down the ARTIOS phase 3b trial results, highlighting the exceptionally low relapse rates, MRI outcomes, and safety findings in patients switching therapies.
At ECTRIMS 2025, a staff neurologist at Cleveland Clinic discussed findings from an observational study on long-term safety risks of ocrelizumab in patients with multiple sclerosis. [WATCH TIME: 3 minutes]
